B
Björn L.D.M. Brücher
Researcher at University of Tübingen
Publications - 114
Citations - 4269
Björn L.D.M. Brücher is an academic researcher from University of Tübingen. The author has contributed to research in topics: Cancer & Esophageal cancer. The author has an hindex of 33, co-authored 109 publications receiving 3936 citations. Previous affiliations of Björn L.D.M. Brücher include Ludwig Maximilian University of Munich & Technische Universität München.
Papers
More filters
Journal ArticleDOI
Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment
Hinrich Wieder,Björn L.D.M. Brücher,Frank B. Zimmermann,Karen Becker,Florian Lordick,Ambros J. Beer,Markus Schwaiger,Ulrich Fink,Jörg Rüdiger Siewert,Hubert J. Stein,Wolfgang A. Weber +10 more
TL;DR: Changes in tumor metabolic activity after 14 days of preoperative chemoradiotherapy are significantly correlated with tumor response and patient survival, and suggests that FDG-PET might be used to identify nonresponders early during neoadjuvant cheMoradiotherapy, allowing for early modifications of the treatment protocol.
Journal ArticleDOI
Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography
Björn L.D.M. Brücher,Wolfgang A. Weber,M. Bauer,Ullrich Fink,Norbert Avril,T. Hubert J. Stein,Martin Werner,Frank Zimmerman,J. Rüdiger Siewert,Markus Schwaiger +9 more
TL;DR: FDG-PET is a valuable tool for the noninvasive assessment of histopathologic tumor response after neoadjuvant radiotherapy and chemotherapy in patients with locally advanced esophageal cancer.
Journal ArticleDOI
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
Stefan Löb,Alfred Königsrainer,Derek Zieker,Björn L.D.M. Brücher,Hans-Georg Rammensee,Gerhard Opelz,Peter Terness +6 more
TL;DR: Although IDO2 is expressed in human tumors, tryptophan degradation is entirely provided by IDO1, and if ongoing clinical studies show a therapeutic effect of d-1MT, this cannot be attributed to inhibition of IDO in tumor cells.
Journal ArticleDOI
Cell-cell communication in the tumor microenvironment, carcinogenesis, and anticancer treatment.
TL;DR: Cell-cell communication involving the components of junctions and their dynamic interplay with the other aspects of communication, including the tumor microenvironment and carcinogenesis, coupling and migration, and aspects of recent research on cell- cell communication are reviewed.
Journal ArticleDOI
Tissue Inhibitor of Metalloproteinases-1 Promotes Liver Metastasis by Induction of Hepatocyte Growth Factor Signaling
Charlotte Kopitz,Michael Gerg,Obul Reddy Bandapalli,Dilek Ister,Caroline J. Pennington,Stephanie Hauser,Christin Flechsig,Hans Willi Krell,Dalibor Antolovic,Keith Brew,Hideaki Nagase,Manfred Stangl,Claus von Weyhern,Björn L.D.M. Brücher,Karsten Brand,Lisa M. Coussens,Dylan R. Edwards,Achim Krüger +17 more
TL;DR: Elevated stromal expression of TIMP-1 promotes liver metastasis in two independent tumor models by inducing the hepatocyte growth factor (HGF) signaling pathway and expression of several metastasis-associated genes, including HGF and HGF-activating proteases, in the liver.